Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Epilepsy Sub-Classification and Optimal Treatment Plan in Post-Stroke Epilepsy: A Single Center Experience
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG) Posters (7:00 AM-5:00 PM)
094
Characterize epilepsy subtypes in post-stroke epilepsy and defining an optimal treatment plan for patients with post-stroke epilepsy in a single center experience.
Post-stroke epilepsy (PSE) is a common complication of stroke, as ischemic and hemorrhagic strokes accounts for about 11% of adult epilepsy cases and 45% of epilepsy cases age of 60 years or older. PSE are thought to be caused by the increase of intracellular Ca2+ and Na+ with a resultant of lower threshold for depolarization, glutamate excitotoxicity, hypoxia, metabolic dysfunction, global hypoperfusion, or hyper-perfusion injury. PSE is a well-known complication in stroke patient; however, the epilepsy characteristics, symptomology, and optimal treatment plan remains unclear.

We performed a retrospective review of the electronic medical records at the University of Utah Health and queried charts of patients with a diagnosis of stroke and epilepsy who were also evaluated on at least one occasion by a Neurologist between January 2000 to October 2019.
We identified over 2000 unique patients with possible diagnosis of post-stroke epilepsy. Patients average age are 68.5±18.1 years (range from 19 to 97), with 55% female. Patients who suffered either ischemic or hemorrhagic stroke and had a diagnosis of PSE confirmed by a neurologist were included in our final cohort. We describe their stroke location, epilepsy classification, current anti-epileptic drugs (AEDs), seizure activities, as well as other demographic data, and clinical data.
 11-40% of stroke patients are diagnosed with PSE up to five years after their stroke; however, specific seizure classification is not identified. Therefore, Neurologists should be familiar with the common epilepsy subtype in PSE to provide an optimal epileptic treatment plan for patients with post-stroke epilepsy.
Authors/Disclosures
Lilly Fagatele (University of Utah Neurology)
PRESENTER 		Ms. fagatele has nothing to disclose.
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Nazanin Sheibani, MD (Tremont) Dr. Sheibani has nothing to disclose.
Cecilia Peterson An immediate family member of Ms. Peterson has received personal compensation for serving as an employee of 100Plus.
No disclosure on file
No disclosure on file
Amir M. Arain, MD, FÂ鶹´«Ã½Ó³»­ (University of Utah) Dr. Arain has nothing to disclose.
Adam De Havenon, MD, FÂ鶹´«Ã½Ó³»­ (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Blake Newman, MD (University of Utah) Dr. Newman has nothing to disclose.